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Paediatric oncology deals with a diverse group of 
cancers some of which have cure rates close to 100% 
(retinoblastoma and Hodgkin lymphoma) while others 
are incurable (brainstem gliomas) or have very low 
survival rates (high-risk neuroblastoma). The past 50 years 
have seen an unprecedented improvement in survival 
from childhood cancers. Most cooperative groups are 
now reporting cure rates exceeding 70% for paediatric 
cancers.[1] Better understanding of cancer biology, 
development of sophisticated response assessment 
tools and development of newer targeted therapies have 
contributed to improved survival to a very large extent. 
In the developed world, treatment-related mortality is 
becoming rare for most standard treatment modalities. 
Therefore, cancer-related mortality is confined to relapse 
and progression of unresponsive cancers.[2]
Unfortunately, the success in cure of childhood cancer is 
not duplicated in resource-poor countries. The reasons 
are manifold and include factors beyond the control 
of the paediatric oncologist. Patient-/family-related 
factors include distance from the treatment facility, 
malnourishment, poor personal and community hygiene 
and abandonment of therapy due to many reasons 
including financial burden. Factors ascribable to poor 
infrastructure and health system include lack of dedicated 
paediatric cancer services to ensure early diagnosis and 
lack of community-based services to support the child on 
treatment. Even for the minority, who manage to overcome 
these challenges and are diagnosed and treated in a 
timely fashion, cure rates are not comparable with those 
in the Western countries. As expected, cancers requiring 
only surgical treatment (retinoblastoma and low-grade 
glioma) and those requiring low-intensity chemotherapy 
(low stage lymphoma and Wilms’ tumour) fair better 
than those requiring multimodality complex protocols 
(neuroblastoma, bone and soft tissue sarcoma).
Acute lymphoblastic leukaemia (ALL) is the most 
common malignancy afflicting children. Improvement in 
the outcome of paediatric ALL has been the prime example 
of the success of combination chemotherapy. Over the past 
half-century, ALL has been transformed from a commonly 
fatal cancer to a highly curable one with the latest studies 
showing cure rates of above 90%. This success has been 
a result of a better understanding of disease biology 
with cancer cytogenetics, development of risk-stratified 
treatment protocols and sophisticated markers of response; 
allowing intensification of therapy for poor responders. 
Most of this success has been a result of a series of 
carefully conducted clinical trials, each building on the 
results of the last.[3] Some resource-poor countries have 
followed this model with encouraging results.[4]
Poor outcome of ALL in Pakistan can be ascribed to all 
of the above factors including patient, health system 
and treatment-related factors. Enthusiastic adoption 
of Western protocols without a full comprehension of 
confounding or prohibitive factors can lead to treatment 
failure and/or high treatment-related mortality.
Improvement in the outcome of cancer therapy in 
Pakistani children requires concerted efforts at social 
and government levels to improve access to cancer care 
and family support. Prospectively collected outcomes 
data should become the basis of carefully designed 
multi-institutional clinical trials. This will help paediatric 
oncologists build on previous success and lessons learnt 
will reduce morbidity and mortality during cancer 
therapy.
Requirements of carrying out reliable research and 
clinical trials include dedicated clinical trials funding, 
accurate and timely data collection and adherence 
to “good clinical practice” that, in turn, necessitates 
institutional research governance infrastructure. Some 
of the larger institutions which already have research 
infrastructure in place can provide leadership in initiating 
prospective clinical trials.
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